Header Logo

Connection

Christopher Hemond to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications Christopher Hemond has written about Multiple Sclerosis.
Christopher Hemond
Connection Strength
9.020
Multiple Sclerosis
  1. Hemond CC, Deshpande M, Berrios-Morales I, Zheng S, Meyer JS, Slavich GM, Cole SW. A single-arm, open-label pilot study of neuroimaging, behavioral, and peripheral inflammatory correlates of mindfulness-based stress reduction in multiple sclerosis. Sci Rep. 2024 06 18; 14(1):14044.
    View in: PubMed
    Score: 0.758
  2. Hemond CC, Gait?n MI, Absinta M, Reich DS. New Imaging Markers in Multiple Sclerosis and Related Disorders: Smoldering Inflammation and the Central Vein Sign. Neuroimaging Clin N Am. 2024 Aug; 34(3):359-373.
    View in: PubMed
    Score: 0.750
  3. Hemond CC, Solomon AJ. Multiple sclerosis can be diagnosed solely with dissemination in space: No. Mult Scler. 2024 May; 30(6):639-641.
    View in: PubMed
    Score: 0.749
  4. Bose A, Khalighinejad F, Hoaglin DC, Hemond CC. Evaluating the Clinical Utility of Epstein-Barr Virus Antibodies as Biomarkers in Multiple Sclerosis: A Systematic Review. Mult Scler Relat Disord. 2024 Apr; 84:105410.
    View in: PubMed
    Score: 0.734
  5. Hemond CC, Baek J, Ionete C, Reich DS. Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study. Mult Scler. 2022 Nov; 28(13):2046-2056.
    View in: PubMed
    Score: 0.661
  6. Hemond CC, Reich DS, Dundamadappa SK. Paramagnetic Rim Lesions in Multiple Sclerosis: Comparison of Visualization at 1.5-T and 3-T MRI. AJR Am J Roentgenol. 2022 07; 219(1):120-131.
    View in: PubMed
    Score: 0.636
  7. Hemond CC, Bakshi R, Tauhid S, Sarrosa R, Ryan M, Kamath V, Thomas J, Edwards KR. Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211033047.
    View in: PubMed
    Score: 0.597
  8. Herman JA, Khalighinejad F, York K, Radu I, Berrios Morales I, Ionete C, Hemond CC. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis. Mult Scler Relat Disord. 2021 Jan; 47:102619.
    View in: PubMed
    Score: 0.590
  9. Bomprezzi R, Chen AP, Hemond CC. Cervical spondylosis is a risk factor for localized spinal cord lesions in multiple sclerosis. Clin Neurol Neurosurg. 2020 12; 199:106311.
    View in: PubMed
    Score: 0.588
  10. Hemond CC, Healy BC, Tauhid S, Mazzola MA, Quintana FJ, Gandhi R, Weiner HL, Bakshi R. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e530.
    View in: PubMed
    Score: 0.524
  11. Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12; 19(1):23.
    View in: PubMed
    Score: 0.524
  12. Hemond CC, Chu R, Tummala S, Tauhid S, Healy BC, Bakshi R. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. Brain Behav. 2018 08; 8(8):e01068.
    View in: PubMed
    Score: 0.503
  13. Hemond CC, Bakshi R. Magnetic Resonance Imaging in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 05 01; 8(5).
    View in: PubMed
    Score: 0.496
  14. Al Gburi M, Mazzola M, Absinta M, Gait?n MI, Reich DS, Dundamadappa SK, Hemond CC. Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter. Mult Scler. 2025 Mar; 31(3):263-277.
    View in: PubMed
    Score: 0.197
  15. Rabin A, Bello E, Kumar S, Zeki DA, Afshari K, Deshpande M, Francis N, Khalighinejad F, Umeton R, Radu I, Qutab F, Kwong D, Kurban M, Hemond C, Richmond JM, Ionete C. Targeted proteomics of cerebrospinal fluid in treatment na?ve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes. Sci Rep. 2024 09 18; 14(1):21793.
    View in: PubMed
    Score: 0.193
  16. Bagnato F, Sati P, Hemond CC, Elliott C, Gauthier SA, Harrison DM, Mainero C, Oh J, Pitt D, Shinohara RT, Smith SA, Trapp B, Azevedo CJ, Calabresi PA, Henry RG, Laule C, Ontaneda D, Rooney WD, Sicotte NL, Reich DS, Absinta M. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain. 2024 Sep 03; 147(9):2913-2933.
    View in: PubMed
    Score: 0.192
  17. Gandhi S, Zelman S, De Armas RE, Hemond C, Levy AN, Singh S, Korzenik J, Jangi S. Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis. Inflamm Bowel Dis. 2022 10 03; 28(10):1614-1617.
    View in: PubMed
    Score: 0.168
  18. Pimentel Maldonado DA, Eusebio JR, Amezcua L, Vasileiou ES, Mowry EM, Hemond CC, Umeton Pizzolato R, Berrios Morales I, Radu I, Ionete C, Fitzgerald KC. The impact of socioeconomic status on mental health and health-seeking behavior across race and ethnicity in a large multiple sclerosis cohort. Mult Scler Relat Disord. 2022 Feb; 58:103451.
    View in: PubMed
    Score: 0.159
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.